Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1

  • C. Nalli Reumatologia e Immunologia Clinica, Spedali Civili e Cattedra di Reumatologia, Università degli Studi di Brescia, Italy.
  • L. Andreoli Reumatologia e Immunologia Clinica, Spedali Civili e Cattedra di Reumatologia, Università degli Studi di Brescia, Italy.
  • M. Motta Neonatologia e Terapia Intensiva Neonatale, Spedali Civili di Brescia, Italy.
  • G.L. Norman INOVA Diagnostics Inc., San Diego, CA, USA, United States.
  • Z. Shums INOVA Diagnostics Inc., San Diego, CA, USA, United States.
  • W.L. Binder INOVA Diagnostics Inc., San Diego, CA, USA, United States.
  • M. Nuzzo Reumatologia e Immunologia Clinica, Spedali Civili e Cattedra di Reumatologia, Università degli Studi di Brescia, Italy.
  • M. Frassi Reumatologia e Immunologia Clinica, Spedali Civili e Cattedra di Reumatologia, Università degli Studi di Brescia, Italy.
  • A. Lojacono Ostetricia e Ginecologia, Spedali Civili di Brescia, Italy.
  • A. Meini Immunologia e Reumatologia Pediatrica, Clinica Pediatrica, Università degli studi di Brescia, Italy.
  • V. Medeghini Immunologia e Reumatologia Pediatrica, Clinica Pediatrica, Università degli studi di Brescia, Italy.
  • T. Avcin Allergologia, Reumatologia e Immunologia Clinica, Ospedale Pediatrico, Policlinico Universitario di Lubiana, Slovenia, Slovenia.
  • P.L. Meroni Allergologia, Immunologia Clinica e Reumatologia, Istituto Auxologico Italiano, Milano, Italy.
  • A. Tincani | tincani@bresciareumatologia.it Reumatologia e Immunologia Clinica, Spedali Civili e Cattedra di Reumatologia, Università degli Studi di Brescia, Italy.

Abstract

Objective: Anti-b2 GPI are a formal laboratory criterion for the antiphospholipid syndrome (APS). They were demonstrated to be a risk factor for thrombosis and fetal losses but can also be detected in patients with systemic autoimmune disease (SAD), in healthy adults individuals and pre-school children. It has been suggested that different subpopulations of anti-b2GPI may carry different pathogenetic potential: autoantibodies against Domain1 seem to be associated with thrombosis; autoantibodies against Domain4/5 have been identifi ed in patients with non-thrombotic conditions. Methods: We studied 48 patients with SAD (32 systemic lupus erythematosus, 16 undifferentiated connettive tissue disease), 64 patients with APS, 57 one-year-old healthy children born to mother with SAD, 33 children with atopic dermatitis. All subjects were IgG anti-b2 GPI positive. The specifi city of anti-b2 GPI was investigated using ELISA research products containing recombinant b2 GPI D1 and D4/5 antigens. Cut-off values are calculated as 95th percentile on 100 NHD. IgG anti-b2 GPI were tested at a validated home-made ELISA routinely performed in our laboratory. No thrombotic events were recordered in patients with SAD and in both groups of children. Results: Patients with SAD and APS showed prevalent reactivity for D1 while children in both groups preferentially recognize D4/5. Conclusions: IgG anti-b2 GPI against D1 seem to cluster in patients with systemic autoimmune conditions. Their pathogenic potential in determine APS manifestations may be mitigated by adequate prophylaxis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Keywords:
Keywords, anti-b2 glycoprotein I antibodies, domains of b2 glycoprotein I, systemic autoimmune diseases
Statistics
  • Abstract views: 744

  • PDF: 434
How to Cite
Nalli, C., Andreoli, L., Motta, M., Norman, G., Shums, Z., Binder, W., Nuzzo, M., Frassi, M., Lojacono, A., Meini, A., Medeghini, V., Avcin, T., Meroni, P., & Tincani, A. (1). Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1. Reumatismo, 63(2), 91-96. https://doi.org/10.4081/reumatismo.2011.91